Should we be combining local tumor therapies with immunotherapies as standard?

被引：3
|
作者：
Baues, Christian [1 ,2 ,3 ]
Schlaak, Max [1 ,4 ]
von Bergwelt-Baildon, Michael [1 ,5 ,6 ]
Theurich, Sebastian [1 ,5 ,7 ]
机构：
[1] Univ Hosp Cologne, Radio Immune Oncol RIO Consortium, Cologne, Germany
[2] Univ Hosp Cologne, Dept Radio Oncol, Cologne, Germany
[3] Univ Hosp Cologne, CyberKnife Ctr, Cologne, Germany
[4] Univ Hosp Cologne, Skin Canc Ctr, Dept Dermatol & Venereol, Cologne, Germany
[5] Univ Hosp Cologne, Ctr Integrated Oncol CIO Koln Bonn, Dept Internal Med, Cologne, Germany
[6] Univ Hosp Cologne, Dept Internal Med, CII, Cologne, Germany
[7] Univ Hosp Cologne, Dept Internal Med, Canc & Immunometab Res Grp, Cologne, Germany
来源：
FUTURE ONCOLOGY | 2017年 / 13卷 / 18期
关键词：
abscopal effect; CTLA4; electrochemotherapy; immune checkpoint inhibition; immunogenic cell death; immunotherapy; ipilimumab; local treatment; nivolumab; PD-1; pembrolizumab; radiotherapy; talimogene laherparepvec; T-VEC; ADVANCED MELANOMA; UNTREATED MELANOMA; RADIATION-THERAPY; IPILIMUMAB; NIVOLUMAB; SURVIVAL; RADIOTHERAPY; COMBINATION;
D O I：
10.2217/fon-2017-0150
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1573 / 1575
页数：3
相关论文
共 50 条
  • [21] Should we shift the paradigm of preclinical models for ARDS therapies?
    Bain, William
    Matute-Bello, Gustavo
    THORAX, 2019, 74 (12) : 1109 - 1110
  • [22] How should we sequence and combine novel therapies in CLL?
    Davids, Matthew S.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2017, : 346 - 353
  • [23] How many tumor indications should be initially screened in development of next generation immunotherapies?
    Chen, Cong
    Deng, Qiqi
    He, Linchen
    Mehrotra, Devan V.
    Rubin, Eric H.
    Beckman, Robert A.
    CONTEMPORARY CLINICAL TRIALS, 2017, 59 : 113 - 117
  • [24] Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and immunotherapies
    Genard, Geraldine
    Lucas, Stephane
    Michiels, Carine
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [25] Combining Immunotherapies with Conventional Cancer Therapies in a Preclinical Model of Treatment-Resistant, High-Risk Neuroblastoma
    Zebertavage, Lauren K.
    Aiken, Taylor
    Erbe-Gurel, Amy
    Schopf, Allison
    Nielsen, Megan
    Katz, Sydney
    Rakhmilevich, Alexander
    Sondel, Paul
    JOURNAL OF IMMUNOLOGY, 2022, 208 (01):
  • [26] SHOULD WE CHANGE OUR PRESENT STANDARD ON INFANT VIABILITY
    HAAS, RL
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1945, 50 (04) : 406 - 411
  • [27] The Standard Account of Moral Distress and Why We Should Keep It
    Joan McCarthy
    Settimio Monteverde
    HEC Forum, 2018, 30 : 319 - 328
  • [28] LEFT ATRIAL VOLUMES: SHOULD WE RESET THE REFERENCE STANDARD?
    Jansen, Katrijn
    Mani, Navin
    Mehrotra, Praveen
    Tan, Timothy
    Rincon, Luis
    Picard, Michael
    Hung, Judy
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E1264 - E1264
  • [29] The Standard Account of Moral Distress and Why We Should Keep It
    McCarthy, Joan
    Monteverde, Settimio
    HEC FORUM, 2018, 30 (04) : 319 - 328
  • [30] Left Atrial Volumes Should We Reset the Reference Standard?
    Jansen, Katrijn
    Mani, Navin
    Mehrotra, Praveen
    Tan, Timothy C.
    Zeng, Xin
    Dinwoodey, Danya
    Picard, Michael H.
    Hung, Judy
    JACC-CARDIOVASCULAR IMAGING, 2014, 7 (05) : 530 - 531
12345